不同剂量他汀类药物在急性心肌梗死早期患者中的应用效果比较

Applicatin effect comparison of different dosage of statins in the early stage of acute myocardial infarction

目的比较不同剂量他汀类药物在急性心肌梗死早期患者中的应用效果。方法选取2017年10月~2019年1月我院收治的60例急性心肌梗死早期患者作为研究对象,根据随机数字表法将其分为实验组和对照组,每组各30例。实验组患者每天口服20 mg瑞舒伐他汀进行治疗,对照组患者每天口服10 mg瑞舒伐他汀治疗,两组患者均连续治疗6个月。比较两组患者的治疗总有效率、血脂指标水平、C-反应蛋白水平、血压和不良反应情况。结果实验组患者的治疗总有效率为96.7%,高于对照组的73.3%,差异有统计学意义(P<0.05);实验组患者治疗后的三酰甘油、总胆固醇、低密度脂蛋白及C-反应蛋白水平均低于对照组,高密度脂蛋白水平高于对照组,差异有统计学意义(P<0.05);实验组患者治疗后的收缩压、舒张压均低于对照组,差异有统计学意义(P<0.05);实验组患者的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论采取20 mg/d瑞舒伐他汀治疗急性心肌梗死早期患者,可以提高患者的临床效果,改善患者的血脂指标、C-反应蛋白水平,降低患者血压,减少不良反应的发生,安全性更高,值得临床推广应用。

Objective To compare the application effect of different dosage of statins in the early stage of acute myocardial infarction. Methods A total of 60 patients with early stage of acute myocardial infarction treated in our hospital from October 2017 to January 2019 were selected as the subjects. They were divided into experimental group and control group by random number table method, with 30 cases in each group. Patients in the experimental group were treated with Rosuvastatin 20 mg/d, while patients in the control group were treated with Rosuvastatin 10 mg/d, and the patients in both groups were treated for 6 months. The total effective rate, blood lipid index, C-reactive protein, blood pressure and adverse reactions of the two groups were compared. Results The total effective rate of the experimental group was 96.7%, higher than that of the control group(73.3%), the difference was statistically significant(P<0.05).The levels of triacylglycerol, total cholesterol, low density lipoprotein and C-reactive protein in the experimental group were lower than those in the control group, and the level of high density lipoprotein was higher than that in the control group, the differences were statistically significant(P<0.05). The systolic and diastolic blood pressure in the experimental group were lower than those in the control group, the differences were statistically significant(P<0.05). The total incidence of adverse reactions in the experimental group was lower than that in the control group, and the difference was statistically significant(P<0.05). Conclusion In the early stage of acute myocardial infarction, 20 mg/d Rosuvastatin can improve the clinical effect, improve the blood lipid index, C-reactive protein level, reduce the blood pressure, reduce the occurrence of adverse reactions, and have a higher safety. It is worthy of clinical application.